Skip Navigation
Skip to contents

Epidemiol Health : Epidemiology and Health


Author index

Page Path
HOME > Browse articles > Author index
Yara Dadalti Fragoso 1 Article
Systematic review of the published data on the worldwide prevalence of John Cunningham virus in patients with multiple sclerosis and neuromyelitis optica
Sonia Patricia Castedo Paz, Luciana Branco, Marina Alves de Camargo Pereira, Caroline Spessotto, Yara Dadalti Fragoso
Epidemiol Health. 2018;40:e2018001.   Published online January 5, 2018
  • 18,075 View
  • 549 Download
  • 26 Web of Science
  • 19 Crossref
AbstractAbstract PDF
John Cunningham virus (JCV) is a polyoma virus that infects humans, mainly in childhood or adolescence, and presents no symptomatic manifestations. JCV can cause progressive multifocal leukoencephalopathy (PML) in immunosuppressed individuals, including those undergoing treatment for multiple sclerosis (MS) and neuromyelitis optica (NMO). PML is a severe and potentially fatal disease of the brain. The prevalence of JCV antibodies in human serum has been reported to be between 50.0 and 90.0%. The aim of the present study was to review worldwide data on populations of patients with MS and NMO in order to establish the rates of JCV seropositivity in these individuals.
The present review followed the PRISMA (Preferred Reporting Items for Systematic Reviews and Meta-Analyses) guidelines and used the following search terms: “JCV” OR “JC virus” AND “multiple sclerosis” OR “MS” OR “NMO” OR “neuromyelitis optica” AND “prevalence.” These terms were searched for both in smaller and in larger clusters of words. The databases searched included PubMed, MEDLINE, SciELO, LILACS, Google Scholar, and Embase.
After the initial selection, 18 papers were included in the review. These articles reported the prevalence of JCV antibodies in the serum of patients with MS or NMO living in 26 countries. The systematic review identified data on 29,319 patients with MS/NMO and found that 57.1% of them (16,730 individuals) were seropositive for the anti-JCV antibody (range, 40.0 to 69.0%).
The median worldwide prevalence of JCV among adults with MS or NMO was found to be 57.1%.


Citations to this article as recorded by  
  • Revisiting JC virus and progressive multifocal leukoencephalopathy
    Angela Rocchi, Ilker K. Sariyer, Joseph R. Berger
    Journal of NeuroVirology.2023; 29(5): 524.     CrossRef
  • Progressive multifocal leukoencephalopathy in the context of newer therapies in hematology and review of new treatment strategies
    Panagiotis T. Diamantopoulos, Konstantinos Kalopisis, Aikaterini Tsatsou, Athina Efthymiou, Nefeli Giannakopoulou, Sevastianos Hatzidavid, Nora‐Athina Viniou
    European Journal of Haematology.2022; 108(5): 359.     CrossRef
  • B cells going viral in the CNS: Dynamics, complexities, and functions of B cells responding to viral encephalitis
    Amber Cardani‐Boulton, Brendan T. Boylan, Volodymyr Stetsenko, Cornelia C. Bergmann
    Immunological Reviews.2022; 311(1): 75.     CrossRef
  • Longitudinal stability of JCV antibody index in Natalizumab treated people with multiple sclerosis
    M. Gaughan, M. Gilligan, I. Patterson, I. McGurgan, S.M. Yap, N. Tubridy, C. McGuigan
    Multiple Sclerosis and Related Disorders.2022; 68: 104251.     CrossRef
  • Progressive multifocal leukoencephalopathy genetic risk variants for pharmacovigilance of immunosuppressant therapies
    Eli Hatchwell, Edward B. Smith, Shapour Jalilzadeh, Christopher D. Bruno, Yassine Taoufik, Houria Hendel-Chavez, Roland Liblau, David Brassat, Guillaume Martin-Blondel, Heinz Wiendl, Nicholas Schwab, Irene Cortese, Maria Chiara Monaco, Luisa Imberti, Rugg
    Frontiers in Neurology.2022;[Epub]     CrossRef
  • Complications neurologiques de l’infection par le virus JC : revue générale
    A. Moulignier, A. Lecler
    La Revue de Médecine Interne.2021; 42(3): 177.     CrossRef
  • The effect of tonsillectomy on John Cunningham virus serological status in multiple sclerosis patients: A retrospective case–control study
    Mirla Avila, Annette Okai, Smathorn Thakolwiboon, Collin O’Bryan, Murali Mohan Reddy Gopireddy, Sasikanth Gorantla
    Multiple Sclerosis Journal.2021; 27(8): 1297.     CrossRef
  • AGA Technical Review on the Medical Management of Moderate to Severe Luminal and Perianal Fistulizing Crohn’s Disease
    Siddharth Singh, Deborah Proctor, Frank I. Scott, Yngve Falck-Ytter, Joseph D. Feuerstein
    Gastroenterology.2021; 160(7): 2512.     CrossRef
  • Disease-modifying therapies and progressive multifocal leukoencephalopathy in multiple sclerosis: A systematic review and meta-analysis
    Shitiz Sriwastava, Saurabh Kataria, Samiksha Srivastava, Shaghayegh Kazemlou, Si Gao, Sijin Wen, Hamidreza Saber, Richa Tripathi, Zubeda Sheikh, Sarah Peterson, Ronald Gwinn, Evanthia Bernitsas
    Journal of Neuroimmunology.2021; 360: 577721.     CrossRef
  • Common Inflammatory Mechanisms in COVID-19 and Parkinson’s Diseases: The Role of Microbiome, Pharmabiotics and Postbiotics in Their Prevention
    Valery Danilenko, Andrey Devyatkin, Mariya Marsova, Madina Shibilova, Rustem Ilyasov, Vladimir Shmyrev
    Journal of Inflammation Research.2021; Volume 14: 6349.     CrossRef
  • Infections in patients diagnosed with multiple sclerosis: A multi-database study
    R. Persson, S. Lee, M. Ulcickas Yood, CAPT M. Wagner, USN, MC, N. Minton, S. Niemcryk, A. Lindholm, A.M. Evans, S.S. Jick
    Multiple Sclerosis and Related Disorders.2020; 41: 101982.     CrossRef
  • Changes in Anti-JCV Antibody Status in a Large Population of Multiple Sclerosis Patients Treated with Natalizumab
    Eleonora Sgarlata, Clara Grazia Chisari, Emanuele D’Amico, Enrico Millefiorini, Francesco Patti
    CNS Drugs.2020; 34(5): 535.     CrossRef
  • Two susceptible HLA-DRB1 alleles for multiple sclerosis differentially regulate anti-JC virus antibody serostatus along with fingolimod
    Mitsuru Watanabe, Yuri Nakamura, Noriko Isobe, Masami Tanaka, Ayako Sakoda, Fumie Hayashi, Yuji Kawano, Ryo Yamasaki, Takuya Matsushita, Jun-ichi Kira
    Journal of Neuroinflammation.2020;[Epub]     CrossRef
  • John Cunningham Virus Status, Seroconversion Rate, and the Risk of Progressive Multifocal Leukoencephalopathy in Polish John Cunningham Virus-Seronegative Patients with Relapsing-Remitting Multiple Sclerosis
    Katarzyna Kapica-Topczewska, Francois Collin, Joanna Tarasiuk, Agata Czarnowska, Monika Chorąży, Anna Mirończuk, Jan Kochanowicz, Alina Kułakowska
    European Neurology.2020; 83(5): 487.     CrossRef
  • The spectrum of progressive multifocal leukoencephalopathy: a practical approach
    T. Bartsch, T. Rempe, F. Leypoldt, C. Riedel, O. Jansen, D. Berg, G. Deuschl
    European Journal of Neurology.2019; 26(4): 566.     CrossRef
  • Prevalence of Anti-JC Virus (JCV) Antibodies in the Multiple Sclerosis (MS) Population in Cyprus: A Retrospective Study
    Sakis Lambrianides, Christiana A. Demetriou, Andis Tillyris, Elena Kkolou, Eftychia Gaglia, Eleni Agkastinioti, Eleni Leonidou, Yiolanda-Panayiota Christou, Savvas S. Papacostas, Kleopas A. Kleopa, Theodoros Kyriakides, Marios Pantzaris
    Neurology Research International.2019; 2019: 1.     CrossRef
  • High Seroprevalence and Index of Anti-John-Cunningham Virus Antibodies in Korean Patients with Multiple Sclerosis
    Su-Hyun Kim, Yeseul Kim, Ji Yun Jung, Na-Young Park, Hyunmin Jang, Jae-Won Hyun, Ho Jin Kim
    Journal of Clinical Neurology.2019; 15(4): 454.     CrossRef
  • Three cases of non-carryover fingolimod-PML
    Jin Nakahara, Laura Tomaske, Kodai Kume, Tadayuki Takata, Masaki Kamada, Kazushi Deguchi, Kenji Kufukihara, Ruth Schneider, Ralf Gold, Ilya Ayzenberg
    Neurology Neuroimmunology & Neuroinflammation.2019;[Epub]     CrossRef
  • Serum anti-JCV antibody indexes in Japanese patients with multiple sclerosis: elevations along with fingolimod treatment duration
    Shinji Aoyama, Masahiro Mori, Akiyuki Uzawa, Tomohiko Uchida, Hiroki Masuda, Ryohei Ohtani, Satoshi Kuwabara
    Journal of Neurology.2018; 265(5): 1145.     CrossRef

Epidemiol Health : Epidemiology and Health